Pipeline

Commercialized Products

Adult Chronic Immune Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • EMA Review
  • Approved

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HC Review
  • Approved

Fostamatinib in Global Markets

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HC Review
  • Approved

Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Japan Phase 3
  • Approved

Clinical Trials**

Warm Antibody AIHA
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

COVID-19
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  •  
  • Phase 3
  • Approved

COVID-19
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  • Phase 2
  • Phase 3
  • Approved

COVID-19 
Target: Spleen tyrosine kinase (SYK)

  • Pre-clinical
  •  
  • Phase 2
  • Phase 3
  • Approved

Immune Disease 
Target: Interleukin receptor associated kinases 1 and 4 (IRAK1/4)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Immune Disease
Target: Receptor-interacting protein kinase (RIP1)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Partnered-Sponsored Trials

Oncology, COVID-19
Target: AXL receptor tyrosine kinase (AXL)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Oncology
Target: Murine double minute 2 (MDM2)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Chronic Asthma
Target: Janus tyrosine kinase (JAK)

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
  • Key:
  • Company-sponsored Trials
  • Select Investigator-sponsored Trials
  • Partner-sponsored Trials

* Please see the TAVALISSE full Prescribing Information
** Investigational compounds in these indications have not been submitted for FDA review
*** National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)

Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors